Kevin Kotler discloses 5.9% AngioDynamics (ANGO) stake in 13G filing
Rhea-AI Filing Summary
Kevin Kotler has filed a Schedule 13G reporting beneficial ownership of 2,421,526 shares of AngioDynamics, Inc. common stock, representing 5.9% of the class as of 01/06/2026. He holds sole voting and dispositive power over these shares and reports the stake as passive, not for influencing control.
The filing notes that 313,495 shares are owned in his individual capacity, while the remainder is held in accounts he manages. He also formally disclaims beneficial ownership beyond his pecuniary interest in the reported securities.
Positive
- None.
Negative
- None.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What stake in AngioDynamics (ANGO) does Kevin Kotler report on this Schedule 13G?
Kevin Kotler reports beneficial ownership of 2,421,526 shares of AngioDynamics common stock, equal to 5.9% of the outstanding class. He has sole voting and dispositive power over these shares, making him a significant but not controlling shareholder based on this disclosure.
Is Kevin Kotler’s AngioDynamics (ANGO) position reported as passive or activist?
The position is reported as passive. Kotler certifies the securities were not acquired and are not held for the purpose of changing or influencing control of AngioDynamics, and are not held in connection with any transaction intended to have that control-related purpose or effect.
Does Kevin Kotler fully acknowledge beneficial ownership of all reported AngioDynamics (ANGO) shares?
No. Kotler expressly disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest in them. The statement clarifies that it should not be considered an admission of beneficial ownership for Section 16 or any other legal purpose.